A P G Crijns
Overview
Explore the profile of A P G Crijns including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spoor D, van den Bogaard V, Sijtsema N, van der Meer P, de Bock G, Langendijk J, et al.
Breast
. 2023 Jun;
70:49-55.
PMID: 37331094
Purpose: To provide more insight into late treatment-related toxicities among breast cancer (BC) survivors by comparing morbidities and risk factors between BC survivors and age-matched controls. Materials And Methods: All...
2.
Errahmani M, Locquet M, Broggio D, Spoor D, Jimenez G, Camilleri J, et al.
Clin Transl Radiat Oncol
. 2022 Nov;
38:62-70.
PMID: 36388244
Purpose: To assess sinoatrial node (SAN) and atrioventricular node (AVN) doses for breast cancer (BC) patients treated with 3D-CRT and evaluate whether "large" cardiac structures (whole heart and four cardiac...
3.
van den Oever L, Spoor D, Crijns A, Vliegenthart R, Oudkerk M, Veldhuis R, et al.
J Med Syst
. 2022 Mar;
46(5):22.
PMID: 35338425
Cardiac structure contouring is a time consuming and tedious manual activity used for radiotherapeutic dose toxicity planning. We developed an automatic cardiac structure segmentation pipeline for use in low-dose non-contrast...
4.
van den Oever L, van Veldhuizen W, Cornelissen L, Spoor D, Willems T, Kramer G, et al.
J Digit Imaging
. 2022 Jan;
35(2):240-247.
PMID: 35083620
Organs-at-risk contouring is time consuming and labour intensive. Automation by deep learning algorithms would decrease the workload of radiotherapists and technicians considerably. However, the variety of metrics used for the...
5.
Hammer C, Maduro J, Bantema-Joppe E, van der Schaaf A, van der Laan H, Langendijk J, et al.
Radiother Oncol
. 2016 Oct;
122(1):45-49.
PMID: 27793444
Background And Purpose: To develop a multivariable prediction model for the risk of grade⩾2 fibrosis in the boost area after breast conserving surgery (BCS) followed by three-dimensional conformal radiotherapy (RT)...
6.
de Graeff P, Crijns A, de Jong S, Boezen M, Post W, de Vries E, et al.
Br J Cancer
. 2009 Jun;
101(1):149-59.
PMID: 19513073
Background: P53, EGFR and HER-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer, but their prognostic impact is still unequivocal. We performed a meta-analysis to more...
7.
de Graeff P, Crijns A, ten Hoor K, Klip H, Hollema H, Oien K, et al.
Br J Cancer
. 2008 Jul;
99(2):341-9.
PMID: 18628764
Ovarian cancer is the most frequent cause of death from gynaecological cancer in the Western world. Current prognostic factors do not allow reliable prediction of response to chemotherapy and survival...
8.
Crijns A, de Graeff P, Geerts D, ten Hoor K, Hollema H, van der Sluis T, et al.
Eur J Cancer
. 2007 Oct;
43(17):2495-505.
PMID: 17949970
Three amino-acid loop extension (TALE) homeobox proteins MEIS and PBX are cofactors for HOX-class homeobox proteins, which control growth and differentiation during embryogenesis and homeostasis. We showed that MEIS and...
9.
de Graeff P, Hall J, Crijns A, de Bock G, Paul J, Oien K, et al.
Br J Cancer
. 2006 Aug;
95(5):627-33.
PMID: 16880779
The prognostic impact of p53 immunostaining in a large series of tumours from epithelial ovarian cancer patients in a two-centre study was analysed. The study population (n=476) comprised of a...
10.
Crijns A, Duiker E, de Jong S, Willemse P, van der Zee A, de Vries E
Int J Gynecol Cancer
. 2006 Mar;
16 Suppl 1:152-65.
PMID: 16515584
In ovarian cancer the ceiling seems to be reached with chemotherapeutic drugs. Therefore a paradigm shift is needed. Instead of treating all patients according to standard guidelines, individualized molecular targeted...